<DOC>
	<DOCNO>NCT03003676</DOCNO>
	<brief_summary>This single center , phase I pilot study sequential ONCOS-102 pembrolizumab patient advance unresectable melanoma progress PD1 blockade . The primary objective study determine safety sequential treatment ONCOS-102 follow pembrolizumab . The protocol aim enroll 6 patient two cohort : prior PD1 monotherapy prior combination PD1 plus ipilimumab combination therapy .</brief_summary>
	<brief_title>A Pilot Study Sequential ONCOS-102 , Engineered Oncolytic Adenovirus Expressing GMCSF , Pembrolizumab Patients With Advanced Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 ( PD1 ) Blockade</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Adults 18 year age old . Histopathologically confirm melanoma injectable cutaneous lymph node metastasis progress opinion treat investigator despite administer Food Drug Administration ( FDA ) approve antiPD1 agent , without ipilimumab , recent systemic intervention . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Measurable disease accord RECIST 1.1 . Acceptable coagulation status : international normalised ratio ( INR ) blood clotting , prothrombin time activate partial thromboplastin time within ≤1.5 x upper limit normal ( ULN ) . Completion local therapy , radiation , surgical resection , injectable immunebased therapy , topical proinflammatory agent , 21 day prior first dose protocol therapy . Resolution stabilization clinically significant immunemediated adverse event prior therapy continue PD1 blockade contraindicate opinion principal investigator . Clinical stability brain metastasis least 4 week prior first day study therapy . Acceptable liver renal function define : Total bilirubin ≤1.5 x ULN ( include patient Gilbert 's Disease ) Aspartate aminotransferase ( AST , SGOT ) , alanine aminotransferase ( ALT , SGPT ) ≤3.0 x ULN Serum creatinine ≤1.5 x ULN Acceptable haematological function define ( Patients transfuse meet haemoglobin entry criterion ) : Haemoglobin ≥10 g/dL Neutrophils ≥1.5 x 10^9/L Platelet count ≥75 x 10^9/L Able provide valid write informed consent . All woman childbearing potential must negative urine serum pregnancy test screening . All patient must agree use barrier contraception ( i.e . condom ) study treatment 2 month last virus treatment 4 month last dose chemotherapy pembrolizumab . A concomitant medical condition require receipt therapeutic anticoagulant opinion treat physician safely hold allow therapeutic injection ONCOS102 tumor biopsy . A concomitant medical condition opinion treat physician would pose unreasonable additional risk therapeutic injection ONCOS102 . Receipt systemic therapy melanoma , antiPD1 agent , recent episode document progression antiPD1 agent ( without ipilimumab ) prior enrollment . Targeted therapy dabrafenib and/or trametinib injectable therapy talimogene laherparepvec allow followed progression antiPD1 therapy . Any symptomatic autoimmune disease ( lupus , scleroderma , Crohn 's disease , ulcerative colitis ) require administration &gt; 10mg prednisone equivalent . Lower dose steroid condition hypophysitis allow . Any prior severe adverse event attribute prior antiPD1 therapy , Principal investigator 's opinion , would contraindicate pembrolizumab administration : Grade 2 high pneumonitis Grade 4 AST ALT elevation Grade 3 high colitis attributable PD1 blockade ; note colitis attributable ipilimumab exclude Note : absence clinical symptom pancreatitis , elevation amylase lipase contraindication therapy trial Known active infection Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) , HIV . Cleared HBV/HCV infection exclusion , HIV infection cluster differentiation 4 ( CD4 ) count &gt; 500 undetectable viral load . Active bacterial , viral , fungal infection , require systemic therapy . History organ transplant . Patients require chronic systemic immunosuppressant , include steroid ( prednisone daily equivalent &gt; 10 mg ) . Brain metastases clinically unstable ( e.g . show unequivocal growth imaging , require radiation therapy , steroid &gt; 10mg prednisone equivalent ) within 4 week first dose study drug . Known severe congenital acquire cellular humoral immunodeficiency common variable immunodeficiency . Women pregnant breastfeed currently plan 3 month end protocol therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>